Ray Gani

411 total citations
17 papers, 321 citations indexed

About

Ray Gani is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Ray Gani has authored 17 papers receiving a total of 321 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 4 papers in Pulmonary and Respiratory Medicine and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Ray Gani's work include Influenza Virus Research Studies (3 papers), Vaccine Coverage and Hesitancy (3 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Ray Gani is often cited by papers focused on Influenza Virus Research Studies (3 papers), Vaccine Coverage and Hesitancy (3 papers) and SARS-CoV-2 and COVID-19 Research (2 papers). Ray Gani collaborates with scholars based in United Kingdom, United States and Spain. Ray Gani's co-authors include Steve Hughes, Gavin Giovannoni, David O. Bates, John Kerrigan, Feng Pan, Jonathan Plumb, Sonja Sorensen, Paul Robinson, Martín Cowie and Jesús Ruiz-Aragón and has published in prestigious journals such as SHILAP Revista de lepidopterología, Heart and The Pediatric Infectious Disease Journal.

In The Last Decade

Ray Gani

15 papers receiving 301 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ray Gani United Kingdom 9 103 96 90 78 45 17 321
Ellen Maxwell Australia 11 32 0.3× 34 0.4× 10 0.1× 41 0.5× 13 0.3× 18 290
Marie-Joëlle Jabagi France 12 58 0.6× 86 0.9× 9 0.1× 12 0.2× 15 0.3× 23 417
Harkirat Singh India 7 126 1.2× 20 0.2× 7 0.1× 13 0.2× 30 0.7× 11 318
Vinícius Lins Ferreira Brazil 14 151 1.5× 11 0.1× 18 0.2× 55 0.7× 14 0.3× 34 368
J. P. O'Malley United States 9 62 0.6× 42 0.4× 40 0.4× 4 0.1× 11 0.2× 11 351
Daniela Gey Denmark 7 86 0.8× 22 0.2× 7 0.1× 38 0.5× 36 0.8× 9 375
Ruoyan Gai Tobe China 10 147 1.4× 31 0.3× 15 0.2× 7 0.1× 18 0.4× 22 348
Matthew T Crim United States 7 179 1.7× 170 1.8× 18 0.2× 5 0.1× 9 0.2× 10 497
Eva Iglesias Flores Spain 10 50 0.5× 14 0.1× 19 0.2× 8 0.1× 14 0.3× 18 273
Marina Bakker Netherlands 8 121 1.2× 32 0.3× 19 0.2× 7 0.1× 24 0.5× 11 391

Countries citing papers authored by Ray Gani

Since Specialization
Citations

This map shows the geographic impact of Ray Gani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray Gani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray Gani more than expected).

Fields of papers citing papers by Ray Gani

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ray Gani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray Gani. The network helps show where Ray Gani may publish in the future.

Co-authorship network of co-authors of Ray Gani

This figure shows the co-authorship network connecting the top 25 collaborators of Ray Gani. A scholar is included among the top collaborators of Ray Gani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ray Gani. Ray Gani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Chanan‐Khan, Asher, et al.. (2025). Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia. Journal of Managed Care & Specialty Pharmacy. 31(5). 482–490.
2.
Gál, Péter, et al.. (2023). De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation. PharmacoEconomics. 41(12). 1629–1639. 1 indexed citations
3.
Standaert, Baudouin, Edmund J. Pezalla, Nadia Demarteau, et al.. (2023). Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget. Vaccines. 11(2). 377–377. 2 indexed citations
4.
5.
6.
Heininger, Ulrich, et al.. (2021). Health Impact and Cost-effectiveness Assessment for the Introduction of Universal Varicella Vaccination in Switzerland. The Pediatric Infectious Disease Journal. 40(6). e217–e221. 12 indexed citations
7.
Azzari, Chiara, et al.. (2020). The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies. SHILAP Revista de lepidopterología. 2 indexed citations
8.
Azzari, Chiara, et al.. (2020). <p>The Cost-Effectiveness of Universal Varicella Vaccination in Italy: A Model-Based Assessment of Vaccination Strategies</p>. ClinicoEconomics and Outcomes Research. Volume 12. 273–283. 22 indexed citations
9.
Ruiz-Aragón, Jesús, et al.. (2020). Estimated cost-effectiveness and burden of disease associated with quadrivalent cell-based and egg-based influenza vaccines in Spain. Human Vaccines & Immunotherapeutics. 16(9). 2238–2244. 13 indexed citations
10.
11.
Huang, Huan, et al.. (2018). A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.. The American Journal of Managed Care. 24(8 Suppl). S132–S137. 6 indexed citations
12.
Hettle, Robert, et al.. (2012). Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium. Respiratory Medicine. 106(12). 1722–1733. 21 indexed citations
13.
Sorensen, Sonja, Ray Gani, Paul Robinson, et al.. (2012). Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. Heart. 98(7). 573–578. 99 indexed citations
14.
Gani, Ray, et al.. (2010). Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD. Primary Care Respiratory Journal. 19(1). 68–74. 17 indexed citations
15.
16.
17.
Gani, Ray, Richard M. Nixon, Steve Hughes, & Christopher Jackson. (2007). Estimating the rates of disability progression in people with active relapsing-remitting multiple sclerosis. Journal of Medical Economics. 10(2). 79–89. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ellen Maxwell Breakdown of academic impact, for papers by Marie-Joëlle Jabagi Breakdown of academic impact, for papers by Harkirat Singh Breakdown of academic impact, for papers by Vinícius Lins Ferreira Breakdown of academic impact, for papers by J. P. O'Malley Breakdown of academic impact, for papers by Daniela Gey Breakdown of academic impact, for papers by Ruoyan Gai Tobe Breakdown of academic impact, for papers by Matthew T Crim Breakdown of academic impact, for papers by Eva Iglesias Flores Breakdown of academic impact, for papers by Marina Bakker
Rankless by CCL
2026